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ABSTRACT
Tumors can develop a blood supply not only by promoting angiogenesis but also 
by forming vessel-like structures directly from tumor cells, known as vasculogenic 
mimicry (VM). Understanding mechanisms that regulate VM is important, as these 
might be exploitable to inhibit tumor progression. Here, we reveal the adhesion 
molecule desmoglein 2 (DSG2) as a novel mediator of VM in melanoma. Analysis 
of patient-derived melanoma cell lines and tumor tissues, and interrogation of The 
Cancer Genome Atlas (TCGA) data, revealed that DSG2 is frequently overexpressed 
in primary and metastatic melanomas compared to normal melanocytes. Notably, 
this overexpression was associated with poor clinical outcome. DSG2+ melanoma 
cells self-organized into tube-like structures on Matrigel, indicative of VM activity, 
which was inhibited by DSG2 knockdown or treatment with a DSG2-blocking peptide. 
Mechanistic studies revealed that DSG2 regulates adhesion and cell-cell interactions 
during tube formation, but does not control melanoma cell viability, proliferation 
or motility. Finally, analysis of patient tumors revealed a correlation between DSG2 
expression, VM network density and expression of VM-associated genes. These studies 
identify DSG2 as a key regulator of VM activity in human melanoma and suggest 
this molecule might be therapeutically targeted to reduce tumor blood supply and 
metastatic spread.
INTRODUCTION
Without access to a blood supply, solid tumors 
cannot grow more than a few millimeters in diameter 
[1]. For many years, it was thought that the growth of 
vascular networks within tumors occurred exclusively via 
the sprouting and extension of pre-existing blood vessel 
networks into tumors via angiogenesis. Indeed, targeting 
this process in the clinic has produced life-prolonging 
therapies for a variety of cancers. However, the benefits 
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obtained from current anti-angiogenesis therapies are 
modest and many cancer types, such as melanoma, 
respond poorly [2]. Thus, blocking classical angiogenesis 
may be only part of the solution to prevent malignant 
tumors from developing a blood supply.
In this context, much attention has recently focused 
on vasculogenic mimicry (VM), the formation of vascular 
networks directly by tumor cells [3, 4]. In VM, hollow 
channels and narrow conduits within tumors are lined with 
basement membrane, similarly to traditional blood vessels. 
However, in contrast to traditional vessels, VM channels 
are lined by tumor cells rather than endothelial cells (EC). 
The biological importance of VM to tumors is becoming 
increasingly clear, with several studies showing that VM 
channels can anastomose (fuse) with conventional blood 
vessels to access the blood supply, and possess lumens 
through which blood actively flows [5-9]. Furthermore, 
the presence of histologically-detected VM networks 
in primary tumors is predictive of poor survival and 
increased metastasis in patients with melanoma [10-14] 
and other cancers [3, 4, 15]. Similarly, in animal models, 
inhibiting VM in solid cancers leads to improved survival 
[16, 17], and a recent study found that breast cancer 
clones with the highest capacity to enter the vasculature 
and establish metastasis were those most efficient at 
generating VM networks [18]. Together, these findings 
highlight the biological and clinical significance of VM. 
Despite this, the molecular mechanisms that regulate VM 
are not well understood, although pathways associated 
with vasculogenesis, embryogenesis and hypoxia have 
been implicated [3, 4].
Desmoglein 2 (DSG2) is a surface-expressed 
adhesion molecule belonging to the cadherin family, 
and has a well-described function in the formation of 
desmosomes, a specific type of cell-cell junction found 
uniquely in epithelia and myocardium [19]. In humans, 
four desmoglein isoforms (DSG1-4) and three desmocollin 
isoforms (DSC1-3) have been identified, all of which 
undergo homotypic and heterotypic interactions to form 
the adhesive interface of desmosomes. Surprisingly, while 
melanoma cells are not thought to generate desmosomes, 
expression of DSG2 in this cell type has been described 
[20-22], though another study failed to detect DSG2 
expression in human melanoma biopsies [23]. The 
biological function of DSG2 in melanoma remains poorly 
defined, although one study has linked its expression to the 
regulation of melanoma cell motility [21].
We recently identified a novel role for DSG2 in 
the endothelial cell lineage (Ebert et al, submitted). 
These studies demonstrated non-desmosome-localized 
expression of DSG2 by ECs and circulating endothelial 
progenitor cells (EPCs), and established a critical role 
for DSG2 in regulating the angiogenic activity of these 
cells. These findings, together with those of others [24], 
suggest an important role for DSG2 in regulating classical 
angiogenesis. Here, we reveal that DSG2 plays an 
analogous, cell-intrinsic role in melanoma by regulating 
VM. These findings suggest that therapeutic targeting of 
DSG2 may allow simultaneous inhibition of both classical 
angiogenesis and VM, and thereby provide a powerful new 
treatment approach for solid tumors such as melanoma.
RESULTS
DSG2 is heterogeneously expressed by melanoma 
cell lines
In a previous study [20], DSG2 expression was 
detected in 2/8 melanoma cell lines. To better understand 
the frequency of DSG2 expression on cultured melanoma 
cells, we performed gene expression microarray analysis 
on a panel of 28 human melanoma cell lines. As shown 
in Figure 1A, DSG2 was clearly expressed in 68% of cell 
lines (19/28), and the levels of DSG2 expression within 
positive lines was markedly heterogeneous. In contrast, 
expression of other desmosomal cadherins (DSG1, 
DSG3, DSC1, DSC2, DSC3) was negligible (Figure 1B), 
revealing that DSG2 is unique within this gene family 
for its expression in a large proportion of melanoma cell 
lines. In silico analysis of data from The Cancer Cell 
Line Encyclopedia (CCLE) [25] confirmed these findings 
(Supplementary Figure S1). Thus, amongst a panel of 
41 additional human melanoma cell lines, DSG2 was 
broadly and heterogeneously expressed while the other 
desmosomal cadherins showed negligible expression.
To evaluate DSG2 protein expression in cell lines 
demonstrating high and low DSG2 gene expression, four 
cell lines from each category were selected for validation 
(Figure 1C). Flow cytometry confirmed ubiquitous 
expression of DSG2 surface protein on each DSG2-high 
cell line, with a similar intensity of expression to that 
observed for desmosome-forming HaCat cells. In contrast, 
DSG2 protein was undetectable or very low in cell lines 
with low gene expression, similar to blood monocytes 
(which lack desmosomes and DSG2 expression; Ebert et 
al, submitted). In DSG2+ cell lines, immunofluorescence 
microscopy revealed diffuse distribution of DSG2 over cell 
membranes as well as intracellularly, particularly within 
perinuclear puncta (Figure 1D). This was in contrast to 
the localization of DSG2 at cell-cell junctions in HaCat 
keratinocytes, where DSG2 is an integral component of 
desmosomes, and the absence of DSG2 immunostaining 
in the LOX-IMV1 cell line, which lacks DSG2 gene 
and protein expression (as shown in Figure 1A and 1C). 
Together, these results demonstrate that (i) in contrast 
to other desmosomal cadherins, expression of DSG2 
is relatively frequent amongst melanoma cell lines, (ii) 
differences in DSG2 gene expression are also reflected 
at the level of protein expression and (iii) DSG2 protein 
displays a non-desmosomal distribution in melanoma cells.
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DSG2 is expressed in primary and metastatic 
melanoma tissue, but not in normal melanocytes
There are conflicting reports regarding DSG2 
expression in patient melanomas [20, 22, 23]. To resolve 
this, we undertook a comprehensive analysis of DSG2 
expression in a large number of patient melanomas using 
two different anti-DSG2 mAbs. Initially, the 6D8 clone 
[26] was used to stain two tissue microarrays (TMAs) 
containing duplicate cores from 96 metastatic (Stage III/
IV) melanomas with detection by immunohistochemistry. 
As shown in Figure 2A, 35% of tumors had clear DSG2 
Figure 1: DSG2 is heterogeneously expressed by human melanoma cell lines. A. Relative DSG2 gene expression was 
determined by microarray analysis of 28 melanoma cell lines. B. For comparison, expression of other desmosomal cadherin genes was 
determined for the same panel of cell lines. C. Four each of DSG2-high and DSG2-low cell lines were selected for validation of microarray 
data by flow cytometry. Known positive (HaCat) and negative (monocyte) populations are shown for comparison. Values within histograms 
represent % positive for DSG2 within marker region after subtracting background. D. Immunofluorescence staining of permeabilized 
melanoma cells and HaCat keratinocytes with DSG2 or isotype matched control mAb, as indicated. Scale bar = 10μm
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staining in both replicate cores compared to an isotype-
matched negative control. Interestingly, the staining 
patterns observed varied markedly in both intensity and 
sub-cellular localization of DSG2, with 12% of positive 
samples demonstrating membranous staining, 35% 
cytoplasmic staining, and the remainder showing mixed 
membranous and cytoplasmic DSG2 expression.
To validate these results and compare DSG2 
expression in primary versus metastatic disease, we 
next evaluated whole tissue sections using a different 
anti-DSG2 mAb, clone 10G11 [27]. A multi-color 
immunofluorescence approach was utilized for these 
experiments, to enable the identification of melanoma 
deposits via co-staining for the melanoma marker S100; 
this was particularly important when analyzing small 
primary tumors. Analysis of primary (stage I/II; n = 46) 
and metastatic (stage III/IV n = 25) tumors revealed DSG2 
expression by S100+ melanoma cells in 39% of primary 
tumors and 24% of metastatic tumors, which was not a 
statistically significant difference (p = 0.294, Fisher’s 
Exact test) (Figure 2B). Of note, the frequency of DSG2+ 
tumors observed in this analysis using the 10G11 mAb 
was very similar to the results obtained in Figure 2A using 
the 6D8 mAb, providing independent validation of the 
proportion of human melanomas that express DSG2.
We next investigated whether DSG2 expression 
varies temporally or spatially in patients with metastatic 
disease. Matched primary and metastatic tumors were 
obtained from eight patients, and multiple metastatic 
tumors were collected simultaneously from three further 
patients via rapid autopsy (Table 1). For the majority 
of patients (6/8), the expression of DSG2 did not vary 
between their primary and metastatic tumors. However, 
one patient had a DSG2- primary tumor and a DSG2+ 
metastasis and a second patient had a DSG2+ primary 
and a DSG2- metastasis. In the autopsy collections, one 
patient had uniformly DSG2+ disease while for the other 
two patients, only 5/6 and 2/5 of their metastatic tumors 
were DSG2+. Therefore, DSG2 can be heterogeneously 
expressed within individuals with metastatic melanoma. 
There was no association between site of metastasis and 
DSG2 expression in this small cohort.
To support our analysis of DSG2 protein, we also 
analyzed RNA sequencing data from The Cancer Genome 
Atlas (TCGA). Of note, several recent publications have 
highlighted the significance of heterogeneity within 
tumor samples subjected to gene expression profiling. 
In particular, it is becoming increasingly recognized that 
the varying stromal content of tumors can dramatically 
influence the outcome of these analyses, including 
data within TCGA [28-30]. Because DSG2 is normally 
expressed by keratinocytes, it was important to filter the 
input dataset to exclude any samples suspected to contain 
significant amounts of normal skin. Initially, we plotted 
the expression of three genes which are tightly restricted 
to the keratinocyte lineage (IVL, KRT14 and BNC) for the 
473 melanoma samples within the TCGA RNA sequencing 
dataset (Supplementary Figure S2A). Each of these genes 
displayed an exponential distribution, being undetectable 
in the majority of samples but showing extremely 
high levels of expression in a small subset of samples. 
Moreover, as expected, the expression of these three 
keratinocyte genes was tightly correlated (Supplementary 
Figure S2B). On the basis of these results, we filtered the 
samples to exclude any with expression of all three genes 
>5CPM, or any two >20CPM. This filtering resulted in 
removal of 46 samples likely to have a high degree of 
contamination with normal skin, leaving 427 samples for 
downstream analysis.
The expression of DSG2 and other desmosomal 
cadherin genes was determined within this filtered 
dataset. As shown in Figure 2C, DSG2 was broadly and 
heterogeneously expressed, while other desmosomal 
cadherin genes (DSG1, DSG3, DSC1, DSC2, DSC3) were 
rarely expressed, and the mean expression level across 
all samples was significantly lower than for DSG2 (p < 
0.001 for all; Kruskal-Wallis test). Interestingly, analysis 
of copy number variation (CNV) predicted using the 
GISTIC algorithm at cBioPortal [31] for a subset of these 
samples revealed that 48/356 tumors (13.5%) displayed 
copy number amplification at the DSG2 gene locus. 
Moreover, the level of DSG2 mRNA was significantly 
increased in this subset of patients compared to samples 
without amplification (Figure 2D), suggesting CNV as one 
possible mechanism contributing to DSG2 up-regulation 
in melanoma, although non-genetic mechanisms are also 
clearly involved. In keeping with our immunostaining 
results, there were no differences in expression of DSG2 
between stages of disease progression in TCGA samples 
(Figure 2E).
To assess whether DSG2 is expressed by 
melanocytes (the cell of origin in melanoma), sections 
of normal adult skin were co-stained for DSG2 and 
the melanocyte marker melan-A. Of 25 individual 
melanocytes analyzed across 4 normal skin samples, 
none showed evidence of DSG2 expression (Figure 2F), 
in keeping with previous work [22]. To better understand 
DSG2 expression within the melanocyte lineage, we also 
performed in silico analysis of a published microarray 
dataset examining changes in gene expression during 
differentiation of human embryonic stem (ES) cells to 
mature melanocytes in vitro [32]. As expected from 
previous studies [33], pluripotent ES cells expressed high 
levels of DSG2 (Figure 2G). However, this was reduced 
upon directed differentiation of ES cells to melanocyte 
precursors and further reduced upon differentiation to 
mature melanocytes.
Together, these data reveal that DSG2 (distinct 
from other desmosomal cadherins) is induced de novo 
in a subset of human melanomas and can be expressed 
throughout the disease course, but may be subject to 
temporal and spatial regulation within individual patients. 
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Figure 2: DSG2 is expressed in human primary and metastatic melanoma tissue. A. DSG2 expression was examined in a 
metastatic melanoma TMA by immunohistochemistry (brown) with hematoxylin nuclear staining (blue). Bar graph summarizes results 
from 96 tumor samples; representative examples are shown on the right. B. DSG2 expression was examined in full-sized tumor tissue 
sections using immunofluorescence, including co-staining with S100 to confirm the identity of melanoma deposits. A summary of staining 
in primary vs metastatic tumors is shown on the left, and examples of a positive and a negative sample are shown on the right. Ctl; control 
IgG. C-E. RNA sequencing data obtained from TCGA was used to determine expression of desmosomal cadherin genes in melanoma 
samples (n = 427). (C) shows expression of each gene in a different color in scatterplot format, whereby each dot represents an individual 
tumor sample. Samples are arranged in order of intensity of expression, to aid visualization of the data. Dotted lines indicate upper and 
lower 10% cut-points used for subsequent analyses. (D) shows DSG2 expression for samples with and without copy number amplification at 
the DSG2 gene locus and (E) shows DSG2 expression values for each disease stage (horizontal lines indicate mean). Groups were compared 
using Mann-Whitney (D) or Kruskal-Wallis (E) tests. F. Normal human skin was examined for DSG2 expression by immunofluorescence, 
using Melan-A to detect melanocytes; representative of n = 4 donors. G. DSG2 expression in microarray dataset GSE54226, comparing ES 
cells and their derivatives induced to differentiate to melanocyte precursors and mature pigmented melanocytes (n = 2-3 clones of each; 
shown as mean ± SEM; ** p < 0.01 by ANOVA). Scale bars = 50μm.
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Moreover, the expression of DSG2 in melanoma might 
represent re-activation of an embryonic pathway that is 
suppressed in normal adult melanocytes.
Overexpression of DSG2 at the mRNA and 
protein level is associated with poor clinical 
outcome
To begin investigating the functional significance 
of DSG2 expression in melanoma, we correlated stage 
II patient survival with DSG2 protein expression (as 
determined in Figure 2B). Figure 3A shows that patients 
with DSG2+ stage II melanomas were more likely to 
develop metastatic disease compared to those with DSG2- 
tumors (HR = 2.34), but this trend was not statistically 
significant in this small cohort (p = 0.22 log-rank test; n = 
22). We therefore performed further analyses using gene 
expression and survival data from the much larger TCGA 
cohort. We stratified samples into DSG2-high and DSG2-
low groups by setting cut points at the top and bottom 10% 
of the DSG2 gene expression range (Figures 2C and 3B), 
and compared survival outcomes in these two groups. As 
shown in Figure 3C, the median overall survival of DSG2-
high patients was 3379 days, compared with 6598 days in 
DSG2-low patients. This equated to a 2.6-fold increased 
rate of death (hazard ratio) for DSG2-high patients (p = 
0.02, log-rank test). These results support the findings 
from our own cohort (Figure 3A) and posit DSG2 as a 
new prognostic marker in melanoma.
DSG2 regulates tube formation by melanoma 
cells
The results presented thus far demonstrate that 
DSG2 is overexpressed in a large fraction of melanomas 
compared to normal melanocytes, and that this 





1 - - lymph node
2 - - lymph node
3 - + dermis
4 + + lung
5 + - lymph node
6 + + lymph node
7 + + soft tissue
8 + + lymph node
Patient
Metastatic tumors collected at autopsy
#1 #2 #3 #4 #5 #6
CA006 DSG2 - - - - - NA
tumor axilla small small small liver
site bowel bowel bowel
CA019 DSG2 + + + + + -
tumor small small liver liver lung lung
site bowel bowel (L lobe) (R lobe) (L) (R)
CA023 DSG2 - + + - - NA
tumor liver liver liver lung brain
site (R lobe) (central) (L lobe) (L)
Tumors were obtained as either matched primary (Stage II) and metastatic (Stage III or IV) pairs (top section), 
or as multiple metastatic tumors collected at autopsy (lower section) and examined for DSG2 expression by 
immunohistochemistry (top) or immunofluorescence (lower). NA; tissue not available. +/-; DSG2 present or absent, 
respectively.
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overexpression is associated with poor clinical outcome. 
We therefore hypothesized that DSG2 regulates at least 
one aspect of melanoma cell biology that contributes to 
tumor growth or spread. Based on our previous studies 
revealing a role for DSG2 in vascular biology (Ebert et al, 
submitted), we reasoned that this key function for DSG2 
in melanoma may be the promotion of VM. To address 
this possibility, three melanoma cell lines expressing high 
levels of DSG2 (C32, SK-Mel-28 and CHL-1; see Figure 
1) were selected for detailed functional analyses. As shown 
in Figure 4A, all three cell lines formed an extensive 
network of tube-like structures within 6 hr of seeding on 
Matrigel, thus mimicking the behavior of ECs on Matrigel 
and demonstrating a high VM capacity of these cells [3, 
4, 13]. To determine a role for DSG2 in regulating this 
process, gene knockdown was performed 48-72 hr prior to 
Figure 3: DSG2 over-expression in melanoma is associated with poor clinical outcome. A. The rate of progression to 
metastatic disease was determined for 22 patients with Stage II (primary) melanomas. Patients were stratified into DSG2+ and DSG2- 
subsets on the basis of immunofluorescence staining (see Figure 2B) and Kaplan-Meier analysis used to determine the time to tumor 
recurrence. B-C. TCGA DSG2 gene expression data was used to identify patients within the top and bottom 10% of the DSG2 expression 
range, as indicated by the dotted lines in Figure 2C. The level of DSG2 gene expression for each group is shown in (B), while a Kaplan-
Meier analysis of overall survival time from initial diagnosis is shown in (C).
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Figure 4: DSG2 regulates the formation of tube-like structures by melanoma cells on Matrigel. A. Photomicrographs 
illustrate tube formation by three DSG2+ cell lines (C32, SK-Mel-28 and CHL-1) 4-6 hr after seeding on Matrigel. B. Validation of gene 
knockdown following treatment of the C32 cell line with DSG2-targeting or control siRNAs. The level of DSG2 mRNA was quantified 
after 48 hr by qPCR (top), or DSG2 surface protein was quantified after 72 hr by flow cytometry (bottom). Graphs show mean ± SEM 
(normalized to control siRNA), pooled from 2 – 4 experiments. C. An example of the effect of DSG2 knockdown on tube formation by C32 
melanoma cells after 6 hr. D. The number of tubes formed per well was quantified for three melanoma cell lines. Data show mean ± SEM 
(normalized to control siRNA) pooled from 3-4 experiments; * p < 0.05 by ANOVA. E. DSG2 blocking peptide was added to CHL-1 cells 
prior to seeding on Matrigel, and tube formation after 3.5 hr was quantified as above. Graph on the left shows tube counts per well (mean 
+/- SEM, pooled from 4 experiments; *** = p < 0.001 by ANOVA). Images on the right show representative results at 500μM peptide. 
Scale bars = 200μm.
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seeding cells on Matrigel. Each of three different DSG2-
targeting siRNAs led to efficient reduction of both gene 
and surface DSG2 protein levels (Figure 4B). When these 
cells were seeded onto Matrigel, marked inhibition of tube 
formation was observed, with DSG2-knockdown cells 
forming fragmented networks or remaining in irregularly 
shaped clusters of cells (see examples in Figure 4C). 
Inhibition of tube formation upon DSG2 knockdown was 
observed in all three cell lines (Figure 4D).
To further test the ability of DSG2 to regulate tube 
formation, we used a 10-amino acid competitor peptide to 
block DSG2 homotypic interactions. This peptide targets 
the DSG2 cell adhesion recognition (CAR) domain and 
has been previously demonstrated to block DSG2-
mediated alveolar morphogenesis by epithelial cells [34] 
and colon carcinoma cell aggregation [35]. When this 
peptide was mixed with CHL-1 melanoma cells prior to 
seeding on Matrigel, striking inhibition of tube formation 
was observed compared to a scrambled control peptide 
(Figure 4E).
Investigating the mechanism by which DSG2 
regulates tube formation
Previous studies have shown that DSG2 can regulate 
several biological processes in addition to its canonical 
function in desmosomal adhesion, including proliferation 
and cell death in epithelial cells [36-38], actin cytoskeletal 
architecture in ECs [24] and melanoma cell migration 
[21]. We thus assessed the effect of DSG2 inhibition on 
these parameters in melanoma cells, to determine whether 
they could contribute to the observed reduction in tube 
formation.
As shown in Figure 5A-5B, there was no change in 
cell viability after either DSG2 knockdown (for 48-72 hr) 
or 4 hr incubation with DSG2 blocking peptide. Similarly, 
melanoma cell proliferation was unaffected by DSG2 
knockdown (Figure 5C). To determine whether DSG2 
regulates cell morphology and cytoskeletal architecture, 
we performed phalloidin staining to detect polymerized 
F-actin structures (Figure 5D and Supplementary Figure 
S3). Analysis of stained cells by confocal microscopy 
confirmed DSG2 knockdown (insets) but revealed no 
consistent changes to cell shape, and the structure of the 
actin cytoskeleton was also largely unchanged. To measure 
cell migration, scratch wound assays were undertaken by 
creating a uniform scratch in confluent cell monolayers 
and then measuring wound thickness every hour, as cells 
migrate in to close the wound. When time-course curves 
were compared (by determining the area under the curve), 
we observed no detectable effect of DSG2 knockdown on 
migration of C32, CHL-1 or SK-Mel-28 cells (Figure 5E). 
To confirm these results in a different assay and investigate 
the behavior of individual cells during tube formation, 
we seeded CHL-1 cells on Matrigel and performed time 
lapse imaging and Time Lapse Analyzer tracking [39] to 
measure the distances travelled by cells during the first 
2 hr of tube formation (Figure 5F and Supplementary 
Movies S1-S4). Cell migration on Matrigel was not 
affected by knockdown with DSG2 siRNA-B, although 
DSG2 siRNA-C (which routinely gave slightly more 
efficient knockdown; see Figure 4B), marginally reduced 
migration. We therefore repeated these experiments with 
C32 cells but found no effect of either siRNA. Thus, 
using two different assays, we could not reproduce the 
reported [21] increase in melanoma cell migration upon 
DSG2 knockdown. Note that, for each of these functional 
assays using DSG2 knockdown, efficiency of knockdown 
was confirmed by flow cytometric analysis of DSG2 
expression on the day of the assay (not shown).
Despite the lack of other desmosomal cadherins, 
DSG2 may nevertheless mediate melanoma cell adhesion 
in a desmosome-independent context, a possibility which 
has been previously proposed but not rigorously tested 
[20, 40]. We therefore measured the ability of C32 cells to 
adhere to each other, by generating confluent monolayers 
of cells (treated with control or DSG2-targeting siRNA) 
and incubating them for 15 mins with fluorescently-
labeled cells also treated with the same siRNA, followed 
by stringent washing. Strikingly, despite the plethora 
of adhesion molecules expressed on melanoma cells, 
reducing expression of just DSG2 produced a significant 
reduction in cell-cell adhesion (Figure 5G, p < 0.01). 
Notably, time lapse imaging of tube formation on Matrigel 
also provided evidence of a role for DSG2 in regulating 
cell adhesion (Supplementary Movies S1-S4). Thus, cells 
with DSG2 knockdown generally failed to form close 
attachments with adjacent cells, instead either spreading 
circumferentially on the Matrigel to form irregular 
patches (CHL-1) or remaining in small, loose clusters 
(C32). Together, these observations suggest that the major 
function of DSG2 in tube formation is to regulate cell-
cell adhesion, thereby stabilizing and strengthening VM 
networks.
DSG2 expression is associated with increased 
occurrence of VM and overexpression of VM-
associated genes in human melanoma
Our mechanistic studies using cell lines revealed 
an important role for DSG2 in promoting melanoma cell 
tube formation on Matrigel, an in vitro correlate of VM. 
We therefore next assessed a potential link between DSG2 
expression and VM occurrence in patient melanomas. 
To quantify VM, tissue sections were stained with anti-
CD31 using immunohistochemistry (to detect ECs) in 
combination with Periodic Acid-Schiff (PAS). This latter 
reagent stains basement membrane structures (including 
those lining both VM channels and normal blood vessels) 
magenta, and is routinely employed to detect VM networks 
in tumors [10-14]. Examples of tumors with pronounced 
VM (i.e. branching networks of PAS+ structures which 
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Figure 5: Effect of DSG2 inhibition on cell survival, proliferation, cytoskeletal structure, migration and adhesion. A-B. 
Cell viability was assessed by 7-AAD staining following 48-72 hr siRNA-mediated knockdown (A) or 4 hr incubation with peptide (B). C. 
Cells were treated with siRNA for 48-72 hr, the cell proliferation reagent WST-1 added, and absorbance measured 90 minutes later. D. C32 
cells transfected with control or DSG2 siRNA were grown on coverslips for 48 hr, stained with DAPI (blue), rhodamine-phalloidin (red) 
and anti-DSG2 (green; insets) and analyzed by confocal microscopy. E. Scratch wound migration assays: wound size was measured every 
hour and time-course curves compared by determining area under the curve. Images show 0 hr and 18 hr time points using SK-Mel-28 cells. 
F. CHL-1 cells (top) or C32 cells (bottom) were seeded on Matrigel and cell migration during the first 2 hr of tube formation monitored 
by time lapse confocal imaging and quantified using the TLA program. Representative plots illustrate centrally-equalized migration tracks 
for individual cells within one field of view. G. Adhesion assays: Fluorescently-labeled C32 cells (treated with control or DSG2-targeting 
siRNA) were incubated for 15 min on top of a confluent monolayer of C32 cells, also treated with the same siRNA. After extensive washing 
in a parallel plate flow chamber, remaining adherent cells were quantified in 4 fields of view. Scale bars = 250μm. For all: bar graphs show 
mean ± SEM, n ≥3 experiments; ns - not significant; * p < 0.05 by ANOVA.
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lack CD31 staining) and with no detectable VM (lack 
of PAS+ networks) are shown in Figures 6A and 6B, 
respectively.
To quantify the density of VM networks, we took 
advantage of the fact that PAS staining also produces a 
red fluorescent signal [41, 42] (Figure 6A-6B insets), 
Figure 6: Expression of DSG2 in patient tumors is associated with increased VM. Tissue sections were assessed for VM 
by co-staining with PAS (magenta) and anti-CD31 (brown) with hematoxylin counter-staining (blue). A-B. Examples of VM+ (A) and 
VM- (B) tissues are shown. Main images depict colorimetric staining; insets show fluorescent images of the same field of view, for easier 
visualization of PAS+ networks. Scale bar = 200μM. C-D. VM was quantified using ImageJ (see Supplementary Materials and Methods). 
For (C), these scores were plotted separately for Stage II tumors falling into the categories of ‘PAS-neg’ (no PAS networks), ‘PAS-low’ (PAS 
networks covering <10% of area, or disconnected arcs only) and ‘PAS-high’ (extensive PAS networks) according to visual examination. 
Each symbol represents an individual tumor; * p < 0.05; *** p < 0.001 by ANOVA. For (D), VM scores were plotted separately for tumors 
identified as DSG2- or DSG2+ by immunofluorescence (see Figure 2B). Each symbol represents an individual tumor, with Stage II tumors 
identified by solid symbols and the multiple tumors collected from Stage IV patients at autopsy identified by patient-specific open symbols; 
** p < 0.01 by unpaired t-test. E. TCGA RNA sequencing data was used to identify tumors within the top and bottom 10% of the DSG2 
expression range, as shown in Figure 3B. A differential gene expression analysis was performed and the list of genes overexpressed by 
the DSG2-high group (see Supplementary Table S1) was subject to Gene Ontology analysis. Graph shows significantly enriched GO-Slim 
terms; where multiple terms within a hierarchy were significantly enriched, only the most specific subclass is shown. Terms with relevance 
to VM are highlighted in green; *** p < 0.001, ** p < 0.01, * p < 0.05.
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in addition to the more frequently reported colorimetric 
reaction. Fluorescent images of each tissue were first 
analyzed in ImageJ using the ‘Tubeness’ algorithm to 
detect branching networks [43]. Networks co-staining 
for CD31 were then subtracted from the image to enable 
calculation of the total area occupied by PAS+CD31- 
networks, as described in Supplementary Materials 
and Methods. This approach for quantifying VM, 
which is usually described qualitatively [10-14], was 
first validated by assessing each tumor histologically 
according to the criteria of Warso et al [11] and 
comparing these results to the calculated VM score 
(Figure 6C). As expected, tumors with extensive PAS+ 
CD31- networks had a significantly higher VM score 
than those which lacked these structures or had very 
limited PAS patterning. Notably, when this quantitative 
approach was used to compare VM levels in DSG2+ and 
DSG2- tumors (defined according the results of Figure 
2 and Table 1), significantly higher VM scores were 
observed in DSG2+ melanomas compared to DSG2- 
melanomas (mean 3.24 vs 1.42; p < 0.01; Figure 6D). 
Thus, DSG2 overexpression is associated with increased 
VM in human melanoma.
Finally, we performed differential gene expression 
analysis of TCGA data to identify genes overexpressed in 
DSG2-high compared to DSG2-low melanomas. A total of 
286 genes was significantly overexpressed (>2-fold; false 
discovery rate (FDR) < 0.005) in the DSG2-high group 
(Supplementary Figure S4 and Supplementary Table S1), 
while 139 genes were underexpressed. Overexpressed 
genes included those associated with EC function (e.g. 
NRP1, EDIL3, EDNRA, AGTR1), collagen production 
(including basement membrane components COL4A3 
and COL4A5) and a progenitor status (e.g. PROM1), as 
well as several proteases involved in modifying ECM 
(e.g. MMP9, MMP1, PRSS21, TMPRSS2 and PLAU). 
DSG2-high tumors also demonstrated overexpression of 
three members of the SERPIN gene family (SERPINB2, 
SERPIND1 and SERPINE1). These genes all encode 
serine protease inhibitors which regulate blood clotting, 
an activity thought to be essential for the generation of 
perfused VM structures. Of note, SerpinE2, another Serpin 
family member which regulates clotting, has recently been 
shown to be critical for VM activity of breast cancer cells 
[18]. When the list of overexpressed genes was subject 
to gene ontology analysis using PANTHER [44], the 
annotations included ‘blood circulation’, ‘anatomical 
structure morphogenesis’, and ‘cell-cell adhesion’, all 
terms relating to the generation and function of vascular 
structures (Figure 6E). Interestingly, several annotations 
associated with embryogenesis were also enriched, in 
keeping with the concept that VM is induced in tumors that 
revert to an embryonic-like state [3, 4]. Thus, melanoma 
cells expressing high levels of DSG2 also express elevated 
levels of VM-associated genes, suggesting that DSG2 is 
part of a broader genetic program which regulates VM in 
tumors.
DISCUSSION
VM is increasingly accepted as an important 
promoter of cancer growth and metastasis. Here, we have 
identified DSG2 as a novel regulator of VM in human 
melanoma. Compared to normal melanocytes, DSG2 
was overexpressed in a substantial fraction of human 
melanoma tissues and cell lines, and its expression in 
patient tumors was associated with enhanced VM, an 
enrichment of VM-associated genes and reduced overall 
survival. In vitro studies confirmed a direct role for 
DSG2 in the formation of VM-like structures. On the 
basis of these findings, we propose that DSG2 is induced 
during tumorigenesis in a large subset of melanoma 
patients and functions to promote the formation of VM 
networks, which in turn may help drive tumor growth and 
progression.
Historically, the principal function ascribed to 
DSG2 has been the formation of desmosomal adhesion 
structures in epithelia and myocardium. However, 
DSG2 is increasingly recognized to also play important 
biological functions unrelated to desmosome formation 
[20, 21, 24, 36-38]. Most notably for the present study, 
recent data implicate DSG2 in regulating the angiogenic 
activity of ECs, whereby loss of function disrupts tube 
formation on Matrigel and in vivo neoangiogenesis, and 
is associated with defective angiogenesis in patients with 
systemic sclerosis [24] (Ebert et al, submitted). Here, 
we demonstrate that DSG2 fulfils a related function 
in melanoma, by promoting VM. This VM-promoting 
activity appears to represent yet another function for 
DSG2 which is independent of desmosomes, as its 
distribution in melanoma was not typical of desmosomal 
localization, and melanoma cells generally lacked co-
expression of desmocollins, which are required to form 
functional desmosomes [45].
The formation of VM channels in tumors, or the in 
vitro correlate of this process – tube formation on Matrigel 
[3, 4, 13] – are highly complex processes. It was therefore 
important to determine the precise activity which DSG2 
controls in melanoma cells during tube formation. Many 
of the non-desmosomal functions ascribed to DSG2 in 
various cell types could be expected to impact on the 
VM capacity of melanoma cells. However, in contrast to 
epithelial cells [36-38], we did not find any role for DSG2 
in regulating the viability or proliferation rate of melanoma 
cells, at least following short-term loss of function. These 
results are in keeping with findings of a previous study 
in melanoma cells [21]. And while DSG2 has been 
suggested to regulate the actin cytoskeleton in ECs [24], 
DSG2 knockdown did not have a similar effect in cultured 
melanoma cells. It remains possible, however, that DSG2 
could regulate other cytoskeletal structures in these cells, 
or be required for active cytoskeletal rearrangements 
during tube formation. Finally, using two different 
approaches, we did not detect any change in melanoma 
cell migration following DSG2 knockdown, which is 
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in contrast to a previous study [21] for reasons that are 
presently unclear. On the other hand, DSG2 knockdown 
did significantly reduce the ability of melanoma cells to 
adhere to each other, suggesting that DSG2 promotes 
VM by mediating intercellular adhesion, presumably in 
a non-desmosomal context. In support, live imaging of 
tube formation in the absence of DSG2 revealed that cells 
underwent initial migration and positioning similar to 
control cells, but at later time-points appeared unable to 
form the intimate cell contacts required for generation of 
a branching network.
VM is thought to occur when tumor cells revert 
to an undifferentiated, embryonic-like state, endowing 
them with the functional plasticity to mimic the behavior 
of ECs [3, 4]. In keeping with this concept, several 
proteins that play a key role in embryogenesis, such as 
Nodal and Notch4, can be re-expressed in aggressive 
melanoma and play a functional role in the VM process 
[46]. We found that DSG2 is expressed at high levels 
by ES cells and down-regulated upon differentiation to 
mature melanocytes, but then re-expressed in a subset of 
melanomas. Furthermore, analysis of TCGA data revealed 
that melanomas overexpressing DSG2 are also enriched 
in genes associated with embryogenesis. We therefore 
propose that DSG2 expression is induced in melanoma 
as part of a genetic program resulting in re-expression 
of embryonic genes, endowing cells with the functional 
plasticity required to undergo VM. Interestingly, although 
DSG2 clearly plays an important role in regulating VM, 
it is not absolutely required for this process, as we have 
identified several melanoma cell lines which lack DSG2 
expression and yet can still form tubes on Matrigel 
(unpublished findings). In addition, not all tumors with 
evidence of VM expressed DSG2. It is likely that DSG2 is 
one of several cadherins which can contribute to VM, and 
indeed, previous studies have implicated VE-cadherin in 
this process [47, 48]. Furthermore, other members of the 
desmosomal cadherin family were expressed at low level 
in a small number of TCGA tumors, and DSG1, DSC2 
and DSC3 were all significantly enriched in the DSG2-
high tumor subset. It would be worthwhile determining 
in future studies whether these molecules also play a 
role in VM, and whether there is a degree of functional 
redundancy, or even cooperativity, amongst family 
members.
The importance of VM to melanoma pathogenesis 
is suggested by its close association with poor survival 
and increased metastasis in at least five separate human 
studies [10-14]. We found that DSG2 overexpression 
in human melanoma is associated with enhanced VM, 
increased expression of VM-associated genes and reduced 
progression-free and overall survival. In addition, DSG2 
directly regulated VM activity (i.e. tube formation) in 
vitro. These data suggest that therapeutic targeting of 
DSG2 in melanoma might block the formation of VM 
networks. On the basis of previous studies, we hypothesize 
that this would in turn reduce tumor growth and 
metastasis. Given the established role of DSG2 in normal 
tissues [19], inhibiting DSG2 in patients could be expected 
to result in some level of toxicity. However, previous 
studies suggest that targeting DSG2 in patients is feasible. 
A small recombinant protein (JO-4) shown to disrupt 
DSG2-mediated adhesion was well tolerated in primate 
pre-clinical models [49], while clinical trials targeting 
the closely related N-cadherin have revealed an excellent 
safety profile for this approach with no dose-limiting 
toxicities, despite extensive expression of N-cadherin on 
normal tissues [50]. These studies raise the possibility 
that DSG2 could be therapeutically targeted in melanoma 
with acceptable toxicity, possibly using the JO-4 reagent, 
an antibody-drug conjugate, or a variant of the peptide 
inhibitor we used in Figure 4E. Importantly, these 
approaches would be expected to reduce both melanoma 
cell-mediated VM and EC-mediated angiogenesis [24] 
(and Ebert et al, submitted), and thereby provide more 
complete inhibition of tumor vascular networks than is 
achievable using current anti-angiogenesis therapeutics [2].
In summary, our observations reveal DSG2 as a 
novel regulator of VM in human melanoma and a marker 
of prognostic significance in this disease. Our data also 
add weight to evidence that DSG2 is unique amongst 
the desmosomal cadherins in its expression and function 
outside the context of desmosomes. Additional studies 
are warranted to further explore the importance of DSG2-
induced VM to melanoma pathogenesis, and to evaluate 
this molecule as a new therapeutic target in melanoma.
MATERIALS AND METHODS
Cell culture
Melanoma cell lines were obtained from American 
Type Culture Collection or the Australasian Biospecimen 
Network-Oncology cell line bank at the Queensland 
Institute for Medical Research (QIMR) and their identity 
confirmed by PCR-based short tandem repeat (STR) 
analysis. Cells were cultured in RPMI containing 10% 
FCS (‘RF-10’; melanoma cells) or DMEM containing 
10% FCS (HaCat cells) under standard conditions 
(37°C, 5% CO2), and periodically confirmed negative 
for mycoplasma using MycoAlert (Lonza). Cultures 
were routinely passaged using trypsin, although prior to 
functional assays, cells were instead detached with 10mM 
EDTA to prevent cleavage of surface molecules.
Functional assays using melanoma cell lines
Tube formation assays were performed on 
Growth-Factor Reduced Matrigel from Falcon using 
Ibidi Angiogenesis culture slides. Tube-like structures 
(defined as elongated multi-cellular structures between 
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groups of cells that are intimately joined, not just loosely 
aligned) were counted in a blinded manner. Scratch 
wound assays were performed using a WoundMaker™ 
and IncuCyte ZOOM® (Essen BioScience) according 
to the manufacturer’s instructions. Proliferation assays 
were conducted using Cell Proliferation Reagent WST-
1 (Roche). To perform adhesion assays, Calcein-labeled 
and siRNA-treated cells were incubated for 15 min on a 
confluent monolayer of C32 cells (treated with the same 
siRNA), followed by washing and quantification of 
bound fluorescent cells. Full details of each assay are in 
Supplementary Materials and Methods.
DSG2 gene knockdown using siRNA
‘Trilencer-27’ siRNA duplexes were purchased from 
Origene. Transfection was performed using Lipofectamine 
RNAiMax (Thermo Fisher) according to the manufacturer’s 
protocol, using 1nM siRNA. On the basis of time course 
experiments, C32 and SK-Mel-28 cells were used in 
experiments 72 hr after knockdown, while CHL-1 cells 
were used 48 hr after knockdown. Knockdown efficiency 
was assessed by flow cytometry as a quality control check 
prior to performing functional assays.
DSG2 function-blocking peptide
The DSG2 ectodomain competitive inhibitor peptide 
and scrambled control peptide were custom synthesized 
and purified by HPLC to ≥95% by Mimotopes (Clayton, 
VIC, Australia). Freeze-dried peptides were reconstituted 
in PBS and aliquots stored at -80°C. Sequences were: 
DSG2 peptide: LTGYALNARG; scrambled control 
peptide: YTRLGANLAG, based on Runswick et al [34]. 
Peptide was pre-mixed with melanoma cells prior to 
seeding on Matrigel.
Gene expression microarray analysis of 
melanoma cell lines
Cells were harvested when 50–80% confluent. 
RNA was extracted (QIAGEN RNeasy kit) and in vitro 
transcribed and biotin labelled cRNA was fragmented 
and hybridized to Affymetrix 1.0ST expression array 
as per manufacturer’s instructions. GeneChips were 
washed and stained in the Affymetrix GeneChip Fluidics 
Station 450 using standard Fluidics Protocol (Fluidics 
protocol FS450_007) and scanned using the Affymetrix 
7G Scanner. The data was RMA normalized using the R 
Bioconductor affy package.
RNA extraction, reverse transcription and 
quantitative PCR (qPCR)
RNA was extracted from cells, reverse transcribed 
and subject to real-time PCR according to standard 
protocols; details are in Supplementary Materials and 
Methods.
Flow cytometry
Cells were stained with anti-DSG2 (clone 6D8; 
Thermo Fisher) or isotype-matched control antibody 
(clone MOPC-21; BD) at 5μg/ml for 20 min at 4°C, 
incubated with secondary antibody, washed and fixed 
in paraformaldehyde. All staining steps were performed 
in complete medium containing FCS, as this was 
found to produce optimal staining for DSG2 (Sun et al, 
manuscript in preparation). Samples were processed 
using a BD Accuri flow cytometer and data analyzed 
using FSC Express (De Novo software). Cell viability 
was determined by staining with 7-Amino-Actinomycin 
D (7-AAD Staining Solution; BD Biosciences) at a 1/20 
dilution for 10 min prior to flow cytometric analysis.
Patient tissues and TMAs
Formalin-fixed paraffin embedded (FFPE) 
melanoma tissues for immunohistochemistry analysis 
(including TMAs) were obtained from SA Pathology 
(Adelaide, Australia). Their use was approved by the 
Human Research Ethics Committee of the Royal Adelaide 
Hospital. TMAs were created using an Advanced 
Tissue Arrayer (Chemicon International). Human FFPE 
melanoma and normal tissues for immunofluorescence 
analysis were obtained from TissuPath and from 
established cohorts (the Melbourne Melanoma Project 
[51] and the CASCADE rapid autopsy program [52]), 
in accordance with the Peter MacCallum Cancer Centre 
Human Research Ethics Committee approved protocol 
10/02.
Immunofluorescence and immunohistochemistry
For staining of cell lines, cells were seeded onto 
coverslips and stained with anti-DSG2 (clone 6D8) together 
with rhodamine-phalloidin. For tissue analysis, sections 
were subject to heat-mediated antigen retrieval followed 
by either immunofluorescence staining using anti-DSG2 
(clone 10G11; LSBio) and anti-S100 (clone Z0311; Dako); 
or immunohistochemistry using anti-DSG2 (clone 6D8) or 
anti-CD31 (rabbit polyclonal; Bethyl Laboratories) together 
with Periodic-Acid Schiff (PAS). Detailed protocols are in 
Supplemental Materials and Methods.
Bioinformatics analysis of publically available 
datasets
Analysis of microarray data generated by Mica et 
al [32] was performed by analyzing Gene Expression 
Omnibus (GEO) dataset GSE45223 using the GEO2R 
analysis tool (http://www.ncbi.nlm.nih.gov/geo/geo2r/). 
Data are pooled from 2 ES cell clones and 3 clones 
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each of melanocyte precursors and mature melanocytes. 
The Cancer Cell Line Encyclopedia dataset [25] was 
interrogated by analyzing GEO dataset GSE36133 using 
GEO2R. To analyze TCGA data, RNA sequencing (RNA-
seqV2) and clinical (Biotab) data were downloaded from 
the Data Portal at http://cancergenome.nih.gov/. Data were 
analyzed in Bioconductor, using the edgeR package to 
perform differential gene expression analysis [53].
Statistics
Statistical analysis was performed using GraphPad 
Prism v5.04. Survival analysis was conducted using 
Kaplan-Meier plots with log-rank tests. Other analyses 
were performed using unpaired Student’s t-test (except 
where results were normalized to an internal control, in 
which case a paired t-test was used) or 1-way ANOVA 
as appropriate. Bonferroni post-tests were used to 
compare individual groups. For data with a non-normal 
distribution, Mann-Whitney and Kruskal-Wallis tests 
with Dunn’s post-test were used instead. Results with p 
< 0.05 were considered significant, and are indicated on 
graphs according to the reporting summary in Prism v5.04, 
whereby * = p < 0.05 but > 0.01; ** = p < 0.01 but > 0.001 
and *** = p < 0.001.
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